HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/4/C1543    most recent 00068.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Fu, D. Articles by Roufogalis, B. D. Search for Related Content PubMed PubMed Citation Articles by Fu, D. Articles by Roufogalis, B. D.

CALL FOR PAPERS
Protein and Vesicle Trafficking, Cytoskeleton

Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation

Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia

Submitted 12 February 2006 ; accepted in final form 21 November 2006

Intracellular traffic of human P-glycoprotein (P-gp), a membrane transporter responsible for multidrug resistance in cancer chemotherapy, was investigated using a P-gp and enhanced green fluorescent fusion protein (P-gp-EGFP) in human breast cancer MCF-7 cells. The stably expressed P-gp-EGFP from a clonal cell population was functional as a drug efflux pump, as demonstrated by the inhibition of daunorubicin accumulation and the conferring of resistance of the cells to colchicine and daunorubicin. Colocalization experiments demonstrated that a small fraction of the total P-gp-EGFP expressed was localized intracellularly and was present in early endosome and lysosome compartments. P-gp-EGFP traffic was shown to occur via early endosome transport to the plasma membrane. Subsequent movement of P-gp-EGFP away from the plasma membrane occurred by endocytosis to the early endosome and lysosome. The component of the cytoskeleton responsible for P-gp-EGFP traffic was demonstrated to be actin rather than microtubules. In functional studies it was shown that in parallel with the interruption of the traffic of P-gp-EGFP, cellular accumulation of the P-gp substrate daunorubicin was increased after cells were treated with actin inhibitors, and cell proliferation was inhibited to a greater extent than in the presence of daunorubicin alone. The actin dependence of P-gp traffic and the parallel changes in cytotoxic drug accumulation demonstrated in this study delineates the pathways of P-gp traffic and may provide a new approach to overcoming multidrug resistance in cancer chemotherapy.

protein traffic; drug resistance in cancer; daunorubicin

This article has been cited by other articles:

				S. Ye, D. P. MacEachran, J. W. Hamilton, G. A. O'Toole, and B. A. Stanton Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif Am J Physiol Cell Physiol, September 1, 2008; 295(3): C807 - C818. [Abstract] [Full Text] [PDF]

				D. Siccardi, K. L. Mumy, D. M. Wall, J. D. Bien, and B. A. McCormick Salmonella enterica serovar Typhimurium modulates P-glycoprotein in the intestinal epithelium Am J Physiol Gastrointest Liver Physiol, June 1, 2008; 294(6): G1392 - G1400. [Abstract] [Full Text] [PDF]

				P. Randhawa, N. A. Farasati, and Y. Huang BK Virus Replication In Vitro: Limited Effect of Drugs Interfering with Viral Uptake and Intracellular Transport Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4492 - 4494. [Abstract] [Full Text] [PDF]